BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 27631159)

  • 1. The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.
    Horvat TZ; Pecoraro JJ; Daley RJ; Buie LW; King AC; Rampal RK; Tallman MS; Park JH; Douer D
    Leuk Res; 2016 Nov; 50():17-20. PubMed ID: 27631159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
    Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
    Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PEGylated
    Verma A; Chen K; Bender C; Gorney N; Leonard W; Barnette P
    Pediatr Hematol Oncol; 2019 Aug; 36(5):277-286. PubMed ID: 31296092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.
    Salzer WL; Asselin B; Supko JG; Devidas M; Kaiser NA; Plourde P; Winick NJ; Reaman GH; Raetz E; Carroll WL; Hunger SP
    Blood; 2013 Jul; 122(4):507-14. PubMed ID: 23741010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Desensitization using pegaspargase in the era of commercially available Erwinia: A single-institution report on efficacy, cost, and resource utilization.
    Feldman K; Aaronson K; Gu T; Ige K; Southworth E; Sanchez L; Stieglitz E
    Pediatr Blood Cancer; 2024 Apr; 71(4):e30891. PubMed ID: 38311802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allergic Reactions With Intravenous Compared With Intramuscular Pegaspargase in Children With High-risk Acute Lymphoblastic Leukemia: A Population-based Study From the Maritimes, Canada.
    MacDonald T; Kulkarni K; Bernstein M; Fernandez CV
    J Pediatr Hematol Oncol; 2016 Jul; 38(5):341-4. PubMed ID: 26925715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegaspargase-induced hypertriglyceridemia in a patient with acute lymphoblastic leukemia.
    Lau KM; Saunders IM; Goodman A
    J Oncol Pharm Pract; 2020 Jan; 26(1):193-199. PubMed ID: 30823860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asparaginase Erwinia chrysanthemi (Erwinaze®): a guide to its use in acute lymphoblastic leukemia in the USA.
    Keating GM
    BioDrugs; 2013 Aug; 27(4):413-8. PubMed ID: 23794007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma.
    August KJ; Farooki S; Fulbright JM; August A; Portnoy JM; Pommert L; Burke MJ; Guest EM
    Pediatr Blood Cancer; 2020 Jan; 67(1):e28021. PubMed ID: 31571395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia.
    Douer D; Aldoss I; Lunning MA; Burke PW; Ramezani L; Mark L; Vrona J; Park JH; Tallman MS; Avramis VI; Pullarkat V; Mohrbacher AM
    J Clin Oncol; 2014 Mar; 32(9):905-11. PubMed ID: 24516026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegaspargase: an alternative?
    Holle LM
    Ann Pharmacother; 1997 May; 31(5):616-24. PubMed ID: 9161659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability and toxicity of pegaspargase in adults 40 years and older with acute lymphoblastic leukemia.
    Daley RJ; Rajeeve S; Kabel CC; Pappacena JJ; Stump SE; Lavery JA; Tallman MS; Geyer MB; Park JH
    Leuk Lymphoma; 2021 Jan; 62(1):176-184. PubMed ID: 32985296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegaspargase: A Review in Acute Lymphoblastic Leukaemia.
    Heo YA; Syed YY; Keam SJ
    Drugs; 2019 May; 79(7):767-777. PubMed ID: 31030380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients.
    Wang B; Relling MV; Storm MC; Woo MH; Ribeiro R; Pui CH; Hak LJ
    Leukemia; 2003 Aug; 17(8):1583-8. PubMed ID: 12886246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia.
    Vrooman LM; Kirov II; Dreyer ZE; Kelly M; Hijiya N; Brown P; Drachtman RA; Messinger YH; Ritchey AK; Hale GA; Maloney K; Lu Y; Plourde PV; Silverman LB
    Pediatr Blood Cancer; 2016 Feb; 63(2):228-33. PubMed ID: 26376459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia.
    Larson RA; Fretzin MH; Dodge RK; Schiffer CA
    Leukemia; 1998 May; 12(5):660-5. PubMed ID: 9593262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
    Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
    Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia.
    Vrooman LM; Supko JG; Neuberg DS; Asselin BL; Athale UH; Clavell L; Kelly KM; Laverdière C; Michon B; Schorin M; Cohen HJ; Sallan SE; Silverman LB
    Pediatr Blood Cancer; 2010 Feb; 54(2):199-205. PubMed ID: 19672973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety profile of Erwinia asparaginase treatment in adults with newly diagnosed acute lymphoblastic leukemia: a retrospective monocenter study.
    Bigliardi S; Morselli M; Potenza L; Coluccio V; Maccaferri M; Paolini A; Colaci E; Fantuzzi V; Faglioni L; Soci F; Nasillo V; Messerotti A; Pedrazzi P; Marietta M; Luppi M; Forghieri F
    Leuk Lymphoma; 2015 Mar; 56(3):770-3. PubMed ID: 24991716
    [No Abstract]   [Full Text] [Related]  

  • 20. Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses.
    Burke PW; Aldoss I; Lunning MA; Devlin SM; Tallman MS; Pullarkat V; Mohrbacher AM; Douer D
    Leuk Res; 2018 Mar; 66():49-56. PubMed ID: 29407583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.